aestheticmedguideAestheticMedGuide
Skin

Alopecia areata treatment: JAK inhibitors, steroids, and what regrowth actually looks like

Alopecia areata is autoimmune hair loss, not pattern baldness. Three FDA-approved JAK inhibitors (Olumiant, Litfulo, Leqselvi) finally treat severe disease — with real efficacy and real risk.

Ran Chen
Ran Chen
11 min read · Published · Evidence-based

Alopecia areata (AA) is the second most common cause of hair loss in the United States, affecting an estimated 7 million Americans. It is an autoimmune disease: the immune system attacks the hair follicles, producing round or patchy hair loss that can progress to loss of all scalp hair (alopecia totalis) or all body hair (alopecia universalis). It is not the same as male- or female-pattern hair loss, which is hormone-driven and covered separately in our androgenetic alopecia guide. Because the mechanism is different, the treatments are different — and for the first time in the history of this disease, they actually work.

The single most important shift in this field is the arrival of oral JAK inhibitors. Between June 2022 and July 2024 the FDA approved three of them for severe alopecia areata — baricitinib (Olumiant), ritlecitinib (Litfulo), and deuruxolitinib (Leqselvi). Before 2022 there was no FDA-approved systemic treatment for severe AA at all; dermatologists managed it with steroids and off-label immunosuppressants that were unreliable and, at high doses, unsafe. This article lays out what the new drugs do, how well they work, who they are and are not for, and where the older options (intralesional steroid injections, topical immunotherapy, minoxidil) still fit. It is educational and not a substitute for care from a board-certified dermatologist.

Why the disease matters, and how severity is measured

Alopecia areata runs a famously unpredictable course. Some patients regrow hair spontaneously; others lose it in waves over decades. The "sine wave" pattern — episodes of loss and regrowth — is classic. Because of that variability, treatment trials measure success against a severity score called the SALT (Severity of Alopecia Tool), which estimates the percentage of scalp with hair loss. A SALT score of 100 is total scalp hair loss; "severe" AA is generally defined as SALT ≥ 50, meaning at least half the scalp is affected. The headline result in every modern trial is the proportion of patients who reach SALT ≤ 20 — at least 80% scalp hair coverage. That is the benchmark to keep in mind when you read the numbers below.

Nail changes (pitting, ridging), eyebrow and eyelash loss, and a personal or family history of other autoimmune conditions (thyroid disease, vitiligo, type 1 diabetes) are common. AA can begin at any age, and roughly half of patients onset before age 21 — which is why a drug approved for adolescents was a meaningful advance.

The JAK inhibitors: why they exist and what they do

The autoimmune attack in AA is driven by signaling through the Janus kinase (JAK) pathway — specifically cytokines like interferon-gamma that recruit T-cells to the follicle. JAK inhibitors switch that signaling off, removing the immune attack so the follicle can cycle again. This is the same drug class used in rheumatoid arthritis and atopic dermatitis. They are oral pills taken once daily, which is part of their appeal — and part of their risk.

Baricitinib (Olumiant) — the first, approved June 2022

On June 13, 2022, the FDA approved baricitinib (Eli Lilly/Incyte) as the first systemic treatment for severe AA in adults. Approval rested on the twin phase 3 trials BRAVE-AA1 and BRAVE-AA2, together enrolling more than 1,200 adults with severe disease. In those trials, 35–40% of patients on the 4 mg daily dose reached SALT ≤ 20 (≥80% scalp coverage) by week 36, with initial regrowth visible as early as 12 weeks and benefit sustained out to roughly three years of follow-up. The labeled dosing starts at 2 mg daily, stepping to 4 mg if response is inadequate, with the option to step back down to 2 mg once an adequate response is achieved — follow the label and the prescriber's plan rather than assuming a fixed dose.

Ritlecitinib (Litfulo) — the one for ages 12+, approved June 2023

Roughly a year later, on June 23, 2023, the FDA approved ritlecitinib (Pfizer). Two things make it distinct. First, it is approved for adults and adolescents 12 and older, making it the first approved treatment for younger patients — a genuine gap, given how many patients are children and teens. Second, it is a more selective inhibitor, targeting JAK3 and the TEC family kinases rather than the broader JAK1/2 spectrum. The phase 2b/3 ALLEGRO trial (718 patients across 18 countries) showed 23% of patients on the 50 mg daily dose reaching ≥80% scalp coverage at six months versus 1.6% on placebo, rising to roughly 45% at one year and 61% at two years on continued treatment.

Deuruxolitinib (Leqselvi) — approved July 2024

In July 2024 the FDA approved deuruxolitinib (Sun Pharma) for severe AA in adults, based on the THRIVE-AA1 and THRIVE-AA2 trials in which about a third of patients reached SALT ≤ 20 by week 24 on the approved 8 mg twice-daily dose (a higher 12 mg trial arm did somewhat better but was discontinued over clot-risk concerns, so 8 mg twice daily is the dose that came to market), with continued improvement through 68 weeks. It is a JAK1/2 inhibitor in the same family as baricitinib, but dosed twice daily rather than once. Beyond scalp coverage, the trials also measured eyebrow and eyelash regrowth with dedicated tools (the BETA and BELA scales), with significant improvement by week 24 — relevant because eyebrow and eyelash loss is one of the most distressing features of AA, and these drugs regrow them in a meaningful share of patients.

What the JAK class cannot promise — and the risk you must weigh

All three carry the FDA boxed warning shared by the JAK class: serious infections, increased mortality (seen in a rheumatoid arthritis post-marketing study comparing tofacitinib to a TNF blocker), malignancy, major adverse cardiovascular events (MACE), and thrombosis. Because of that signal, the FDA generally steers these drugs away from patients with active serious infection, a history of cancer, or elevated cardiovascular or clot risk, and toward patients in whom the benefit of treating severe, life-altering disease clearly outweighs it. Routine lab monitoring (blood counts, lipids, liver tests) is standard. The common day-to-day side effects are less alarming but real and worth knowing before starting: upper respiratory infections, headache, acne, nausea, and rash, along with the lab shifts (elevated cholesterol, blood-count changes) that the monitoring is there to catch.

Two expectations set the JAK class apart from a cure. First, onset is weeks to months, not days — regrowth typically begins around 8–12 weeks, and the week-36 and week-24 endpoints in the trials reflect that. If a patient has had no response at six to nine months, that is the point at which a dermatologist reassesses rather than waits indefinitely. Second, and more important: the effect is maintenance, not cure. Relapse rates after stopping are high — in the order of 80% of patients lose their regrown hair when they discontinue, mirroring what was seen with the older off-label JAK tofacitinib, where relapse often began within weeks of stopping. For most patients this is a long-term medication, and any plan to stop it should be made with that in mind. These are not casual prescriptions, and they are not first-line for a single small patch of hair loss — they are the option that changed severe, extensive disease.

The options that came first — and still matter

Not every patient needs a JAK inhibitor. For limited disease, the older toolkit is effective and far lower-risk.

  • Intralesional triamcinolone acetonide injections remain the first-line treatment for localized (patchy) AA. A meta-analysis of intralesional steroid concentrations found pooled regrowth rates of about 63% below 5 mg/mL and roughly 81% at 5 mg/mL, with injections every 4–6 weeks. The tradeoff is that 10 mg/mL improves response slightly but raises the risk of skin atrophy, which is why 2.5–5 mg/mL is the usual range, used cautiously near the hairline.
  • Potent topical corticosteroids are an alternative for children who cannot tolerate injections and for wider areas; allow at least three months before judging response, and watch for skin thinning with prolonged use.
  • Topical minoxidil (and increasingly low-dose oral minoxidil) is an adjunct that supports regrowth once the immune attack is controlled, but it does not by itself stop the autoimmune process — it is a fertilizer, not a firewall. Platelet-rich plasma is a separate, evidence-thinner adjunct covered in our PRP hair restoration guide.
  • Contact immunotherapy (DPCP or SADBE) — applying a sensitizer to deliberately create a mild allergic contact dermatitis on the scalp — is a long-standing option for extensive disease, particularly in patients who are not candidates for or decline systemic therapy. It is effective in a meaningful subset but requires repeated clinic visits, is messy and unpredictable, and is not formally FDA-approved for AA.
  • Excimer 308 nm light can help patchy disease.

For extensive disease unresponsive to the above, JAK inhibitors are now the first-line systemic option — a genuine change from even five years ago, when dermatologists had no approved systemic drug to offer.

What it costs

JAK inhibitors are expensive specialty drugs — list prices run into the thousands per month — and access usually runs through insurance with prior authorization, typically reserved for severe (SALT ≥ 50) disease after conservative therapy has failed. Manufacturer copay and patient-assistance programs exist. The older options are dramatically cheaper: intralesional triamcinolone is a generic injected in a routine office visit, and topical minoxidil is inexpensive over the counter. The realistic financial conversation is not "is a JAK inhibitor worth it" in the abstract — it is whether your specific insurance will cover it for your severity, and what your out-of-pocket cap is.

What to ask a dermatologist

  • How severe is my disease — what is my SALT score, and does that qualify me for systemic therapy? Severity, not anxiety, drives the JAK decision.
  • Given my age, which JAK inhibitor fits? Ritlecitinib is the one approved down to age 12; baricitinib and deuruxolitinib are adults-only.
  • What is my cardiovascular, infection, and cancer risk, and does the boxed warning change the choice for me? A responsible prescriber screens for these before starting.
  • If I start a JAK inhibitor and it works, do I stay on it forever? Long-term safety data are still maturing; relapse on stopping is common, so ask about the maintenance plan.
  • For my patchy disease, are we trying intralesional steroid first? For limited AA, that is still the right starting point.
  • What adjuncts (minoxidil, nutrition) actually help, and which are a waste? Patients get a lot of supplement advice; a dermatologist can separate signal from noise.

Alopecia areata is one of the great recent success stories in dermatology — a disease that went from having no approved systemic treatment to having three in 25 months. But "approved and effective" is not the same as "right for everyone." The patients who do best are the ones whose treatment is matched to the severity of their disease, with an honest accounting of what the new drugs can and cannot do.

Sources

Topics
Hair RestorationSafetyRegulatoryCost
Ran Chen
Contributing Editor
Ran Chen

Founder, AestheticMedGuide. Life-sciences operator covering aesthetic devices, injectables, and the industry behind them. Previously global market-access lead across pharma and medtech.

Follow on LinkedIn →

Keep reading from Skin

See all →
Devices · 10 min read

miraDry for underarm sweating: what the only permanent hyperhidrosis device actually does

miraDry is the only FDA-cleared device that permanently destroys underarm sweat glands with microwave energy. It is not for hands or feet, and the…

Injectables · 12 min read

How to Verify Dermal Filler Legitimacy in Hong Kong: Clinic Vetting and Product Red Flags

Hong Kong's GN-00 update classifies dermal fillers as medical devices. Here is how to verify product authenticity, vet clinics, and spot red flags…

Skin · 10 min read

PRP for Skin and Hair: What the Evidence Actually Supports

Platelet-rich plasma is marketed for everything from wrinkles to hair loss. Here is what clinical studies show, what PRP cannot do, what it costs,…